BIO-Europe® 2016: BioNTech's Sean Marett explains Genentech deal rationale

November 22, 2016
Chief operating officer of BioNTech, Sean Marett, talks to Mike Ward, global director of content for Informa Pharma Intelligence, about the German firm's recent co-development deal with Roche company, Genentech. On the sidelines of the recent BIO-Europe® partnering conference, held in Cologne Germany, Marett outlines the benefits of this collaboration, such as access to the US market and regulatory expertise. This deal will be highlighted as part of a deal case study session at The One Nucleus Genesis meeting in London on December 1, 2016.
Previous Video
BIO-Europe® 2016: Denali deal and F-star’s innovative asset centric business model
BIO-Europe® 2016: Denali deal and F-star’s innovative asset centric business model

Jane Dancer, chief business officer at F-star—a Cambridge, UK-based biotech—chats with Mike Ward, global di...

Next Video
BIO-Europe® 2016: Karus CEO highlights niche indications for oncology innovation
BIO-Europe® 2016: Karus CEO highlights niche indications for oncology innovation

Karus Therapeutics CEO, Simon Kerry, talks to Scrip senior writer, Lucie Ellis, during the recent BIO-Europ...